HomeComparePRSN vs ABBV

PRSN vs ABBV: Dividend Comparison 2026

PRSN yields 3030.30% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PRSN wins by $500360607186.71M in total portfolio value
10 years
PRSN
PRSN
● Live price
3030.30%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$500360607186.81M
Annual income
$469,859,227,990,298,900.00
Full PRSN calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — PRSN vs ABBV

📍 PRSN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPRSNABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PRSN + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PRSN pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PRSN
Annual income on $10K today (after 15% tax)
$257,575.76/yr
After 10yr DRIP, annual income (after tax)
$399,380,343,791,754,050.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, PRSN beats the other by $399,380,343,791,732,160.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PRSN + ABBV for your $10,000?

PRSN: 50%ABBV: 50%
100% ABBV50/50100% PRSN
Portfolio after 10yr
$250180303593.46M
Annual income
$234,929,613,995,162,300.00/yr
Blended yield
93.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PRSN
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PRSN buys
0
ABBV buys
0
No recent congressional trades found for PRSN or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPRSNABBV
Forward yield3030.30%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$500360607186.81M$104.7K
Annual income after 10y$469,859,227,990,298,900.00$25,725.73
Total dividends collected$498252908594.85M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PRSN vs ABBV ($10,000, DRIP)

YearPRSN PortfolioPRSN Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$313,730$303,030.30$11,559$438.51+$302.2KPRSN
2$9,220,718$8,885,026.99$13,494$640.86+$9.21MPRSN
3$253,918,671$244,052,501.99$15,951$945.97+$253.90MPRSN
4$6,552,701,214$6,281,008,236.19$19,152$1,413.89+$6552.68MPRSN
5$158,496,977,633$151,485,587,333.73$23,443$2,146.38+$158496.95MPRSN
6$3,594,020,691,580$3,424,428,925,512.90$29,391$3,321.96+$3594020.66MPRSN
7$76,416,745,778,469$72,571,143,638,478.27$37,948$5,265.87+$76416745.74MPRSN
8$1,523,841,939,473,922$1,442,076,021,490,960.80$50,795$8,596.74+$1523841939.42MPRSN
9$28,505,961,865,899,772$26,875,450,990,662,680.00$71,034$14,549.41+$28505961865.83MPRSN
10$500,360,607,186,811,600$469,859,227,990,298,900.00$104,715$25,725.73+$500360607186.71MPRSN

PRSN vs ABBV: Complete Analysis 2026

PRSNStock

Perseon Corporation, formerly known as BSD Medical Corporation, was a life sciences company specializing in the development, manufacture, marketing, and servicing of medical systems for cancer treatment using heat therapy. Their flagship product, the MicroThermX® microwave ablation system, utilized precision-guided microwave energy to ablate diseased soft tissue. The company distributed its products across the United States, Europe, and Asia.

Full PRSN Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PRSN vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PRSN vs SCHDPRSN vs JEPIPRSN vs OPRSN vs KOPRSN vs MAINPRSN vs JNJPRSN vs MRKPRSN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.